Project Grant R21AI190491
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$466K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This $431,750 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop a safer and more effective vaccine for monkeypox (MPXV) and smallpox. The grant aims to establish a mouse model to evaluate the virulence of different MPXV strains and test the efficacy of a novel, highly attenuated, replication-competent strain of vaccinia virus as a vaccine. The research builds on prior...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $221,105.00 to the University of Arkansas for Medical Sciences to investigate how APOBEC3 enzymes impact poxvirus evolution, with a focus on Monkeypox (MPOX) virus. The research aims to elucidate the mechanisms by which APOBEC3 enzymes drive MPOX genome diversification, which could enable prediction of MPOX evolution...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $254,250 to New York University (NYU) from July 1, 2025 to June 30, 2027. The funding supports research to understand how pathogenic alphaviruses, such as chikungunya virus, infect and spread through human microvascular endothelial cells. The research aims to identify viral and host factors that restrict alphavirus...
This Project Grant award of $536,871 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to identify pan-arenavirus sites of vulnerability through machine learning and artificial neural network molecular screening of small molecules against arenavirus glycoprotein complexes (GPC) and RNA polymerases (RNAP). The proposed research seeks to define molecular specificities and commonalities across...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the dynamics and evolution of HIV Gag and GagPol processing. The $752,745 award aims to use molecular dynamics simulations, single-molecule FRET imaging, and cryo-electron tomography to probe the structure and dynamics of Gag and GagPol that enable ordered processing by the viral...
This federal Project Grant award, valued at $722,026, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to investigate mechanisms of neuroinvasion, neuroinflammation, and cell senescence that contribute to the severe neurological damage and high mortality associated with Powassan virus (POWV) infection in the elderly. The research aims to reveal age-dependent...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $318,085 to support research on the role of antibodies in controlling virus infections through Fc-dependent mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytolysis (CDC). The research aims to elucidate the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $843,620 to Albert Einstein College of Medicine to develop broadly protective human monoclonal antibody therapies against alphaviruses. The key goals are to: 1) engineer Fc mutations to enhance the in vitro and in vivo properties of broadly neutralizing antibodies, 2) perform viral escape studies to define mechanisms...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $440,700.00 to New York University School of Medicine to conduct research focused on improving HIV vaccine design. The key goals are to: 1) Design and validate an immunogen targeting the V2B neutralization epitope on the HIV/SIV viral spike, and 2) Test the combination of vaccine-elicited anti-V2B...
This Project Grant award of $1,454,386.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports fundamental research to better understand the epigenetic regulation of the HIV-1 viral RNA cap. The research aims to define the structural basis of HIV cap hypermethylation and its linkage to modulating host innate immune signaling, with the goal of developing new treatments to neutralize deleterious...